The future outlook for Tiziana Life Sciences depends heavily on the successful advancement and upcoming clinical data readouts of its lead drug candidate, intranasal foralumab. As the company progresses through crucial Phase 2 clinical trials targeting neurodegenerative and neuroinflammatory conditions like non-active secondary progressive multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis, positive results could validate its innovative nasal immunotherapy platform. However, like many clinical-stage biotechnology firms, its long-term viability also relies on securing additional capital financing, forming strategic pharmaceutical partnerships, and successfully navigating regulatory approval pathways.